参考文献/References:
[1]Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J].BMJ,2020(369):m997. [2]刘子琪.中国糖尿病患病率的流行病学调查研究状况[J].中华老年多器官疾病杂志,2015(14):550. [3]杨文英.中国糖尿病的流行特点及变化趋势[J].中国科学:生命科学,2018,48(8):812-819. [4]Hwang S,Park J,Kim J,et al.Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy[J].Journal of Diabetes&Its Complications,2017,31(12):1704-1709. [5]Perez-Matos MC,Morales-Alvarez MC,Mendivil CO.Lipids:A Suitable Therapeutic Target in Diabetic Neuropathy[J].Journal of Diabetes Research,2017(2017):6943851. [6]Einarson TR,Acs A,Ludwig C,et al.Economic Burden of Cardiovascular Disease in Type 2 Diabetes:A Systematic Review[J].Value Health,2018,21(7):881-890. [7]Gunton J,Delhanty P,Takahashi S,et al.Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2[J].J Clin Endocrinol Metab,2003,88(3):1323-1332. [8]Tingting Z.Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes[J].Journal of Molecular Endocrinology,2009,42(1):57-66. [9]Janine JG.Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice[J].Diabetes,2014,63(3):880-891. [10]Kashfi K,Rosen CL,Aslan M.Obesity,Type-2 Diabetes and Cancer:Mechanistic Insights[J].Critical Reviews in Oncogenesis,2019,24(3):285-305. [11]Ning F,Zhang D,Xue B,et al.Program obotQDP.Synergistic effects of depression and obesity on type 2 diabetes incidence in Chinese adults[J].J Diabetes,2019,12(1):142-150. [12]Apolzan JW,Venditti EM,Edelstein SL,et al.Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study[J].Annals of Internal Medicine.2019,170(10):682-690. [13]Worsley R,Jane F,Robinson PJ,et al.Metformin for overweight women at midlife:a double-blind,randomized,controlled trial[J].Climacteric the Journal of the International Menopause Society,2015,18(2):270-277. [14]Action to Control Cardiovascular Risk in Diabetes Follow-On(ACCORDION)Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On(ACCORDION) Study Group.Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes(ACCORD)Follow-On Study[J].Diabetes Care,2016,39(7):1089-1100. [15]Paul SK,Klein K,Majeed A,et al.Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes[J].Journal of Diabetes,2016,8(3):354-362. [16]Indhavivadhana S,Rattanachaiyanont M,Wongwananurak T,et al.Effect of metformin on cardiovascular risk factors in middle‐aged Thai women with metabolic syndrome:A randomized placebo‐controlled trial[J].Journal of Obstetrics and Gynaecology Research,2020,46(7):1193-1202. [17]Odawara M,Kawamori R,Tajima N,et al.Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus[J].Diabetol Int,2017,8(3):286-295. [18]Burton JH,Johnson M,Johnson J,et al.Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels[J].J Diabetes Sci Technol,2015,9(4):808. [19]Lamounier RN,Geloneze B,Leite SO,et al.Hypoglycemia incidence and awareness among insulin-treated patients with diabetes:the HAT study in Brazil[J].Diabetology and Metabolic Syndrome,2018,10(1):83. [20]Kuan IHS,Savage RL,Duffull SB,et al.The Association between Metformin Therapy and Lactic Acidosis[J].Drug Saf,2019,42(12):1449-1469. [21]Salpeter SR,Greyber E,Pasternak GA,et al.Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus[J].Archinternmed,2010,4(1):CD002967. [22]Lalau JD,Kajbaf F,Arnouts P,et al.Mortality and metformin use in patients with advanced chronic kidney disease[J].Lancet Diabetes&Endocrinology,2015,3(9):680-681. [23]Boucaud-Maitre D,Ropers J,Porokhov B,et al.Lactic acidosis:relationship between metformin levels,lactate concentration and mortality[J].Diabet Med,2016,33(11):1536-1543. [24]Khan A,Shafiq I,Shah H.Prevalence of Vitamin B12 Deficiency in Patients with Type II Diabetes Mellitus on Metformin:A Study from Khyber Pakhtunkhwa[J].Cureus,2017,9(8):e1577. [25]Kancherla V,Elliott JL,Patel BB,et al.Long-term Metformin Therapy and Monitoring for Vitamin B12 Deficiency Among Older Veterans[J].Journal of the American Geriatrics Society,2017,65(5):1061-1066. [26]Pflipsen MC,Oh RC,Saguil A,et al.The Prevalence of Vitamin B12 Deficiency in Patients with Type 2 Diabetes:A Cross-Sectional Study[J].Journal of the American Board of Family Medicine,2009,22(5):528-534. [27]Albai O,Timar B,Paun DL,et al.Metformin Treatment:A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus[J].Diabetes Metab Syndr Obes,2020(13):3873-3878. [28]Volarevic V,Misirkic M,Vucicevic L,et al.Metformin aggravates immune-mediated liver injury in mice[J].Archives of Toxicology,2015,89(3):437-450. [29]Wolfe D,Kanji S,Yazdi F,et al.Drug induced pancreatitis:A systematic review of case reports to determine potential drug associations[J].PLoS One,2020,15(4):e0231883. [30]Svare A.A patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea:a case report[J].Cases J,2009(2):156. [31]Czarnowicki T,Ramot Y,Ingber A,et al.Metformin-induced leukocytoclastic vasculitis:a case report[J].American Journal of Clinical Dermatology,2012,13(1):61-63. [32]American Diabetes Association.9.Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes-2020[J].Diabetes Care,2020,43(Suppl 1):S98-S110. [33]Proks P,Reimann F,Green N,et al.Sulfonylurea stimulation of insulin secretion[J].Diabetes,2002,51(Suppl 3):S368-S376. [34]Foster RH,Plosker GL.Glipizide.A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus[J].Pharmacoeconomics,2000,18(3):289-306. [35]Mogensen UM,Andersson C,Fosbol EL,et al.Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study[J].Diabetes Res Clin Pract,2015,107(1):104-112. [36]Müller G.The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl[J].Molecular Medicine,2000,6(11):907-933. [37]Müller G.Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade[J].FEBS Lett,2002,531(1):81-87. [38]Kokic S,Radman M,Capkun V,et al.Comparative assessment of the treatment of type 2 diabetes mellitus[J].Annals of Saudi medicine,2002,22(3-4):163-166. [39]González-Ortiz M,Guerrero-Romero JF,Violante-Ortiz R,et al.Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus[J].Journal of Diabetes and Its Complications,2009,23(6):376-379. [40]Kabadi UM,Kabadi M.Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes[J].Diabetes Research and Clinical Practice,2006,72(3):265-270. [41]Kawamori R,Kaku K,Hanafusa T,et al.Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus[J].Journal of Diabetes Investigation,2014,5(1):72-79. [42]Yin J,Deng H,Qin S,et al.Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes:a meta-analysis of randomized controlled trials[J].Diabetes Research and Clinical Practice,2014,105(3):e10-e15. [43]Qin C,He W,Zhu C,et al.Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet[J].International Journal of Pharmaceutics,2014,466(1-2):276-285. [44]Florkowski DCM.Management of Co-Existing Diabetes Mellitus and Dyslipidemia[J].American Journal of Cardiovascular Drugs,2002,2(1):15-21. [45]Nie JM,Li HF.Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus[J].Experimental and Therapeutic Medicine,2017,14(3):2521-2526. [46]Achari AE,Jain SK.Adiponectin,a Therapeutic Target for Obesity,Diabetes,and Endothelial Dysfunction[J].International Journal of Molecular Sciences,2017,18(6):1321. [47]Li Y,Tan J,Wang Q,et al.Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome:a randomized controlled trial[J].Fertility and Sterility,2020,113(1):197-204. [48]Filipova E,Uzunova K,Kalinov K,et al.Effects of pioglitazone therapy on blood parameters,weight and BMI:a meta-analysis[J].Diabetology&Metabolic Syndrome,2017(9):90. [49]Shaienko ZO,Bobyreva LY.Combination of metformin and pioglitazone and its effect in treatment of comorbid pathology[J].Wiadomosci Lekarskie,2018,71(2 pt 2):278-280. [50]Ali DE,Shah M,Ali A,et al.Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome:A Randomized Clinical Trial[J].Hormone and Metabolic Research,2019,51(11):714-722. [51]Lu CH,Yang CY,Li CY,et al.Lower risk of dementia with pioglitazone,compared with other second-line treatments,in metformin-based dual therapy:a population-based longitudinal study[J].Diabetologia,2018,61(3):562-573. [52]Ross SA,Gulve EA,Wang M.Chemistry and Biochemistry of Type 2 Diabetes[J].Chem Rev,2004,104(3):1255-1282. [53]Salemi Z,Rafie E,Goodarzi MT,et al.Effect of Metformin,Acarbose and Their Combination on the Serum Visfatin Level in Nicotinamide/Streptozocin-Induced Type 2 Diabetic Rats[J].Iranian Red Crescent Medical Journal,2016,18(3):e23814. [54]Derosa G,Franzetti I,Querci F,et al.Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy:A Placebo-Controlled Trial[J].Pharmacotherapy,2015,35(11):983-990. [55]Osonoi T,Saito M,Hariya N,et al.Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin[J].Peptides,2016(86):118-125. [56]Drucker DJ.The biology of incretin hormones[J].Cell Metabolism,2006,3(3):153-165. [57]Dou J,Ma J,Liu J,et al.Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes:Results from the START study,a multicentre,randomized,double-blind,active-controlled,phase 3 trial[J].Diabetes,Obesity&Metabolism,2018,20(3):590-598. [58]Mathieu C,Herrera Marmolejo M,González González JG,et al.Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes[J].Diabetes,Obesity&Metabolism,2016,18(11):1134-1137. [59]Yan J,Yao B,Kuang H,et al.Liraglutide,Sitagliptin,and Insulin Glargine Added to Metformin:The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease[J].Hepatology(Baltimore,Md),2019,69(6):2414-2426. [60]Gadzhanova S,Pratt N,Roughead E.Use of SGLT2 inhibitors for diabetes and risk of infection:Analysis using general practice records from the NPS Medicine Wise Medicine Insight program[J].Diabetes Research&Clinical Practice,2017(130):180-185. [61]Shyangdan DS,Uthman OA,Waugh N.SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus:a systematic review and network meta-analysis[J].BMJ Open,2016,6(2):e009417. [62]Nauck MA,Del Prato S,Meier JJ,et al.Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin:a randomized,52-week,double-blind,active-controlled non inferiority trial[J].Diabetes Care,2011,34(9):2015-2022. [63]Tan X,Hu J.Combination therapy for type 2 diabetes:dapagliflozin plus metformin[J].Expert Opinion on Pharmacotherapy,2016,17(1):117-126.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(06):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(06):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(06):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(06):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(06):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2022,35(06):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(06):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[8]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Medical Information,2022,35(06):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[9]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Medical Information,2022,35(06):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[10]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行
健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,31(06):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]